Outlook Therapeutics, Inc.
OTLK
$2.41
-$0.2901-10.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 53.81% | 113.27% | 9.10% | -27.78% | -55.87% |
| Total Depreciation and Amortization | 20.56% | 46.45% | 85.88% | 157.69% | 13.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -153.03% | -184.38% | -374.47% | -15.48% | 257.23% |
| Change in Net Operating Assets | 179.90% | 179.06% | 236.64% | -163.49% | -203.02% |
| Cash from Operations | 12.58% | -9.94% | -41.66% | -60.09% | -59.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -456,886.49% | -316,342.31% | 90.98% | 99.96% | 99.93% |
| Issuance of Common Stock | -45.70% | -60.73% | 986.02% | 99.08% | 112.65% |
| Repurchase of Common Stock | -- | -- | 66.11% | 66.11% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -47.02% | -60.60% | 1,112.38% | 23.20% | 30.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,272.56% | -1,202.02% | 88.91% | -241.19% | -121.91% |